This mechanism, previously reported in renal cell carcinoma treated with AXI (45, 66), involves reduced Keap1 expression, increased Nrf2 expression, and overall decreased susceptibility to AXI. This evidence concerns the gene KEAP1 and renal cell carcinoma.